MedTrace Logo

Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain

NCT05304468 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 452

Last updated 2025-03-21

No results posted yet for this study

Summary

To study the 2-year PFS (progression-free survival) of patients with stage II-III nasopharyngeal carcinoma treated with induction chemotherapy followed by two different doses of intensity modulated radiation therapy plus concurrent cisplatin chemotherapy

Conditions

  • Nasopharyngeal Carcinoma

Interventions

RADIATION

IMRT

Patients in experimental group received reduced dose IMRT

DRUG

induction chemotherapy

cisplatin-based induction chemotherapy for two cycles

DRUG

cisplatin concurrent chemotherapy

cisplatin 100mg/m2, for two(60Gy) or three cycles(70Gy)

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Hai Qiang Mai, Dr · Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-11
Primary Completion
2026-10-29
Completion
2029-10-29

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05304468 on ClinicalTrials.gov